Sorry, you need to enable JavaScript to visit this website.

Skip to main content

Search

Peter Lebowitz, M.D., Ph.D.

Peter Lebowitz

As Global Therapeutic Area Head of Oncology,  Peter Lebowitz, M.D., Ph.D. has end-to-end responsibility for Oncology Research & Development, from discovery through development and life cycle management. He leads a global team focused on combining internal and external innovation approaches to discover and develop new solutions for oncologic and hematologic diseases with high unmet medical need.

Prior to taking on the Therapeutic Area Head role, Peter was Head of the Hematologic Malignancy Disease Area. In this role, he was responsible for strategic oversight and execution of the Janssen hematologic malignancy drug discovery and development programs. Before joining Janssen, Peter was Vice President in both early and late-stage clinical development for another leading pharmaceutical company, where he successfully filed 10 Investigational New Drug (IND) applications with the United States Federal Drug Administration (FDA), played a major role in the global registration of three oncology drugs and led major projects from preclinical discovery through pivotal Phase 3 trials.

Prior to joining the industry, Peter was Assistant Professor of Medicine, Division of Hematology/Oncology at the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center in Washington, D.C., where he established an independently funded translational and clinical research program and was a Principal Investigator on numerous clinical research trials. Peter graduated from Harvard University in Cambridge, Massachusetts and earned his M.D. and Ph.D. from the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. He then completed his hematology/oncology fellowship at the National Cancer Institute, National Institutes of Health in Bethesda, Maryland.